Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 7/20 | 0.49 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.49 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126220 | 0.83 | MAPK1 (0.64) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL1524058 | 0.80 | MAPK1 (0.72) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL29394047 | 0.78 | MAPK1 (0.69) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL358730 | 0.78 | MAPK1 (0.69) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL6125034 | 0.78 | MAPK1 (0.63) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL28805237 | 0.77 | MAPK1 (0.67) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL306375 | 0.77 | ALDH1A1 (0.64) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL29580152 | 0.77 | ALDH1A1 (0.64) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL2149474 | 0.77 | MAPK1 (0.61) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL232696 | 0.77 | TDP1 (0.61) | MAPK1TSHRALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | claimed |
| EP-0128563-B1 | IMPROVED ANTIFOGGANT PROCESS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-04 | — | — | EP | claimed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | claimed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | claimed |
| EP-0045570-B1 | USE OF ORGANIC HALOGEN COMPOUNDS TO REDUCE OR PREVENT FOG IN NEGATIVE-WORKING SILVER HALIDE EMULSIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-28 | — | — | EP | claimed |
| WO-2023224108-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | 株式会社GF・Mille | 2023-11-23 | — | — | WO | disclosed |
| US-11780874-B2 | Nucleoside derivative and use thereof | YAMASA CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20230265120-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11643432-B2 | Nucleoside derivative and use thereof | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230011179-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20220220134-A1 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-07-14 | — | — | US | disclosed |
| WO-1997000866-A1 | PESTICIDAL TRIS-OXIMINO HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 1997-01-09 | — | — | WO | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0243959-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4870074-A | Substituted benzamide derivatives, for enhancing gastrointestinal motility | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0243959-A1 | Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-04 | — | — | EP | disclosed |
| CN-86104207-A | The pesticidal use of many halogen alkene derivatives | — | 1987-04-01 | — | — | CN | disclosed |
| US-4472191-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265120-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | PNP, NT5C3B, NUDT1 | MAPK1 1437/4885TSHR 233/4885VCAM1 4345/4885 |
| US-11643432-B2 | Nucleoside derivative and use thereof | PNP, NT5C3B, NUDT1 | MAPK1 1385/4885TSHR 247/4885VCAM1 4346/4885 |
| US-20230011179-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | NT5C3B, NUDT1, PNP | MAPK1 1434/4885TSHR 968/4885VCAM1 4602/4885 |
| US-11780874-B2 | Nucleoside derivative and use thereof | NSUN2, NSUN3, ADAR | MAPK1 2479/4885TSHR 444/4885VCAM1 4751/4885 |
| US-20220220134-A1 | PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME | PHPT1, CD4, CD81 | MAPK1 1989/4885TSHR 2445/4885VCAM1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.